VTT starts to investigate Bayer Schering Pharma's preclinical anti-cancer compounds

The VTT Technical Research Centre of Finland and Bayer Schering Pharma AG, Germany have signed a two-year research contract to study the mode of action of a Bayer Schering Pharma's preclinical cancer drugs. As part of this contract, VTT will use its new gene and cancer biology methods such as the 3D-cell culture model developed at VTT's Medical Biotechnology unit in Turku, Finland.

In the research, VTT will utilise newly developed 3D cancer cell culturing model that enables the study of the cells in an environment that better resembles the conditions in the human body as compared to the conventional 2D cell culture models. The model also allows for improved analyses on the invasive and metastatic behaviour of cancer cells. Through this methodology, VTT scientists can better predict the drug's efficacy and investigate the molecular mechanisms of action of small compounds.

"Over the past five years, we have invested heavily in R&D and we have become leading specialists in the field of molecular cancer research. Our work and technologies have greatly benefited clients and this has now translated into major new business assignments," says the project leader Dr. Marko Kallio, VTT's Senior Research Scientist. Through these actions, VTT aims to increase its impact on the international pharmaceutical sector.

This new contract furthers the collaboration between VTT and Bayer Schering Pharma AG and acknowledges the respected position VTT has gained within the pharmaceutical industry.

VTT's Medical Biotechnology knowledge centre develops and applies new sophisticated research technologies for drug development and diagnostic purposes. The focus of the unit is on identifying primary driver genes and the targets of genetic alterations in cancer. The unit also works to find small molecule inhibitors that prevent the growth and metastasis of various types of cancer. In addition, it develops and utilises versatile recombinant antibody methods and plant biotechnology tools for the needs of pharmaceutical and food industries. Over 100 people work at VTT's Medical Biotechnology knowledge centre on different commercial and academic projects.

About VTT Technical Research Centre of Finland
VTT Technical Research Centre of Finland is the biggest contract research organization in Northern Europe. VTT provides high-end technology solutions and innovation services. From its wide knowledge base, VTT can combine different technologies, create new innovations and a substantial range of world-class technologies and applied research services, thus improving its clients' competitiveness and competence. Through its international scientific and technology network, VTT can produce information, upgrade technology knowledge and create business intelligence and value added to its stakeholders.

http://www.vtt.fi/?lang=en

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...